Device-Based Therapy for Resistant Hypertension: An Up-to-Date Review

Link to article at PubMed

High Blood Press Cardiovasc Prev. 2022 Sep 30. doi: 10.1007/s40292-022-00539-0. Online ahead of print.


Hypertension is the major risk factor for cardiovascular morbidity and mortality. Matter of fact, untreated hypertension can worsen the overall health, whereas pharmacotherapy can play an important role in lowering the risk of high blood pressure in hypertensive patients. However, persistent uncontrolled hypertension remains an unsolved condition characterized by non-adherence to medication and increased sympathetic activity. This paper will review the non-pharmacological treatments for resistant hypertension (RH) that have emerged in recent years. In addition, the technologies developed in device-based RH therapy, as well as the clinical trials that support their use, will be discussed. Indeed, the novel device-based approaches that target RH present a promising therapy which has been supported by several studies and clinical trials, whereas drug non-adherence and high sympathetic activity are known to be the main causes of RH. Nevertheless, some additional aspects of these RH systems need to be tested in the near future, with a particular focus on the device's design and availability of randomized controlled trials.

PMID:36178479 | DOI:10.1007/s40292-022-00539-0

Leave a Reply

Your email address will not be published. Required fields are marked *